Vaccine companies searching for 1-shot dose of COVID-19 vaccine.
New vaccine technologies are, however, being developed -- ones that only need one shot, but generate a sustained, yet controlled, immune response.
For example, the Arcturus vaccine developed by Payne and his colleagues uses a special technique. The vaccine contains a small piece of genetic material, which not only instructs the body to produce a protein that will trigger an immune response, but also adds an extra packet of instructions that effectively helps turbocharge the amount of protein produced.
The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange in New York, Sept. 17, 2019. The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange in New York, Sept. 17, 2019.But with current data, it isn't clear whether the vaccine can generate immunity after just one dose. Amidst ongoing questions about the nature and duration of coronavirus immunity, it might be the case that these vaccines will need booster doses later down the line.
"There are two aspects of vaccine durability -- one is the antibody response, the other is the T-cell response," Payne told ABC News."Most vaccines generate antibodies, but what everyone wants to get is T-cells. If you can do both, you can use a single shot and be done."Editor's Picks
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exclusive: China-backed hackers 'targeted COVID-19 vaccine firm Moderna'Chinese government-linked hackers targeted biotech company Moderna Inc, a U.S.-based coronavirus vaccine research developer, this year in a bid to steal data, according to a U.S. security official tracking Chinese hacking.
Read more »
U.S. government to launch 'overwhelming' COVID-19 vaccine campaign by NovemberThe Trump administration anticipates launching a far-reaching promotions campaign by November to encourage Americans to get vaccinated against the coronavirus, contingent on evidence that a successful vaccine will be available roughly by year end, a senior administration official said.
Read more »
Johnson & Johnson sees promising COVID-19 vaccine results after testing on monkeysJohnson & Johnson took a step forward with its COVID-19 vaccine candidate, releasing promising data after testing on monkeys and announcing the start of human testing.
Read more »
J&J starts human study of COVID-19 vaccine after promising monkey dataWhen exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and five out of six were protected from infection as measured by the presence of virus in nasal swabs, according to the study published in the journal Nature. 'This gives
Read more »
Large U.S. COVID-19 vaccine trials will exclude pregnant women for nowThe first two COVID-19 vaccines to enter large-scale U.S. trials will not be tested in pregnant women this year, raising questions about how this vulnerable population will be protected from the coronavirus, researchers told Reuters.
Read more »
Fauci optimistic Covid-19 vaccine will be widely availableUnder direction from the White House, federal health authorities are carrying out a plan dubbed Operation Warp Speed to manufacture 300 million doses of a vaccine on a compressed timeline.
Read more »